ClinicalTrials.gg
CompletedNCT05079035Updated Sep 19, 2025

Lyophilized and Micronized Particulate Human Amniotic and Umbilical Cord (TTAX03) for KL Grade 3-4 Knee OA

A Phase 2 interventional study of TTAX03 and Saline in Knee Osteoarthritis, Knee Pain Chronic and Knee Arthritis, sponsored by BioTissue Holdings, Inc. Completed at 10 sites in United States. Open to participants aged 35 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-09-19.

Sponsored by BioTissue Holdings, Inc · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2025, 1 year 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
35 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 796 studies in Osteoarthritis, Knee with a site in United States — 109 open to participants now, 153 under way, 15 of them phase 3. Osteoarthritis, Knee · United States.

Enrollment
297th of 691
90 · median 72
Started
2021
with 59 others
Phase 2
111 of 796
13 open now
Registered
609th of 796
by date

Among the 796 studies in Osteoarthritis, Knee with a site in United States, this one is the 297th largest by enrollment of the 691 interventional ones that give a count, is one of 60 that started in 2021, is one of 111 in phase 2, and was the 609th registered.

Osteoarthritis, Knee

3,295 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

109 of the 796 studies in Osteoarthritis, Knee with a site in United States are open now. Recruiting first, the newest first:

104 more — sign in →

All 109 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 383 Osteoarthritis, Knee studies recruiting now, 177 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 35 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 796 studies in Osteoarthritis, Knee with a site in United States, or all of them as a file.
02

Study summary

It is hypothesized that a single Intra-articular Injection of TTAX03, 100mg in 2mL of saline, will have more benefit with respect to the proportion of responders 12 weeks post-injection than an equal volume of saline, based on the OMERACT-OARSI responder criteria.

Read the detailed description

This trial is designed as a Phase 2 randomized, placebo controlled, double-blinded parallel design to be conducted at multiple sites throughout North America. One dose level of TTAX03 (100 mg) will be tested against an equal volume of saline, which is the suspension vehicle (i.e., excipient). Each subject will receive a single IA injection into the knee under local anesthesia, with two safety follow-up visits in the first eight days and a third at the end of two weeks post injection. Subsequent visits will occur at the end of 6 and 12 weeks for evaluation of response, with the end of 12 weeks being the primary endpoint. Additional visits will occur at 6, 9 and 12 months (end of weeks 26, 39, 52) to evaluate duration of benefit and overall impression of change from baseline, as well as safety. The primary endpoint will be assessed at 12 weeks post receiving the assigned Intra-articular injection.

03

Conditions studied

  • Knee Osteoarthritis
  • Knee Pain Chronic
  • Knee Arthritis
04

Who can participate

Ages eligible
35 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able and willing to provide written
  • ≥ 35 and ≤ 85 years of age (until a cap of 30 subjects \< 50 years of age is reached, at which point this will convert to ≥ 50 and ≤ 85 years of age)
  • Able to reliably complete the KOOS self-administered questionnaire
  • Clinical diagnosis of OA of the index knee, with pain onset more than one year prior to screening according to subject recall
  • KL grade 3 or 4 in the index knee
  • Pain score (KOOS) over the past week ≥ 70 in the index knee at Screening (the index knee will be the more painful knee by ≥ 20 in the case of bilateral disease)
  • A ≥ 3 months history of insufficient pain relief from IA hyaluronic acid or a ≥ 3 months history of insufficient pain relief from IA , unless they are medically for the subject
  • A ≥ 3 months history of insufficient pain relief from other currently recommended treatments, including weight loss and physical therapy
  • Any two of the following:

    • Severe knee pain or stiffness that limits everyday activities, including walking, climbing stairs, and getting in and out of chairs. Finding it hard to walk more than a few blocks without significant pain and need to use a cane or walker
    • Moderate or severe knee pain while resting, either day or night
    • Chronic knee inflammation and swelling that does not improve with rest or medications
  • ≤ 40 kg/m2
  • Adequate bone marrow function ( > 1000 × 109 /L, ≥ 100,000 × 109 /L, ≥ 10 g/dL)
  • Adequate hepatic function (/ALT ≤ 1.5 × , total ≤ 1.2 × ULN)
  • Adequate renal function (creatinine ≤ 1.2 × ULN)
  • Negative urine test for opioids (including synthetic opioids)
  • If female and of , willingness to use effective during the study.

Exclusion criteria

Exclusion Criteria:

  • Cognitive impairment, mental illness, neuroses or untreated depression that would preclude understanding or reliably completing the patient reported outcome measures
  • Non-ambulatory, bedridden, or with active fibromyalgia, radiculopathy, painful peripheral neuropathy, vascular insufficiency, hip OA or other joint disease severe enough to prevent assessment of knee pain or causing functional impairment
  • Current use of opioid analgesics, or positive urine laboratory test for opiates during the screening period
  • Hyaluronic acid, , rich plasma or stem cells IA knee injections within the prior 3 months, oral or intramuscular corticosteroids within the prior 2 months
  • Scheduled knee arthroscopy or knee surgery in either knee within 12 weeks from enrollment
  • Known or suspected joint infection of either knee
  • History of knee ligament surgery in the past 12 months
  • Acute injury to the knee in the past 3 months resulting in difficulty walking for more than 24 hours
  • History of inflammatory joint diseases, crystalline diseases such as gout or pseudogout, systemic lupus, rheumatoid arthritis, disease or Crohn's disease
  • Previous repair of a cruciate ligament, osteochondral autograft transfer, mosaicplasty, subchondral surgery (subchondroplasty) or previously diagnosed subchondral insufficiency fracture
  • Comorbid conditions that include the following: known other causes of arthritis (infectious arthritis, or psoriatic arthritis), osteomyelitis, cardiopulmonary disease that limits walking more than knee pain, bone or Paget's disease involving the lower extremities.
  • Psoriasis or other acute or chronic inflammatory conditions or infection affecting the skin over the index knee
  • Symptoms of locking, intermittent block to range of motion or loose body sensation which could indicate meniscal displacement or an intraarticular loose body in the index knee
  • Use of anticoagulants (except for ≤ 81 mg of aspirin per day) or a history of any coagulopathy or bleeding disorder, sickle cell disease
  • History of substance abuse in the past 2 years
  • Prior or current use of systemic medications (other than corticosteroids for arthritis), chemotherapy, or history of organ transplant (kidney, heart, lung)
  • Prior radiation therapy to the index knee
  • Prior treatment with CLARIX FLO, NEOX FLO, or injectable birth tissue products for any indication
  • Concurrent treatment, or treatment in the past 90 days, with any agent
  • Severe concurrent illness which, in the view of the investigator, would interfere with this 52 week study
  • Any condition which, in the opinion of the investigator, would make a patient a poor candidate for this study
  • Positive blood pregnancy test or known pregnancy
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    Experimental: TTAX03

    TTAX03 is a sterile, lyophilized and micronized particulate human AM and UC product manufactured using aseptic processing followed by terminal sterilization by gamma irradiation in compliance with current Good Tissue Practices (cGTP) and current Good Manufacturing Practices (cGMP) to preserve extracellular matrices and growth factors/cytokines therein without any living cells. TTAX03 is suspended in a volume of 2.0mL of sterile, preservative free 0.9% NaCl.

    Biological: TTAX03

  • Placebo comparator
    Control: Saline

    2.0mL of sterile, preservative free 0.9% NaCl alone

    Biological: Saline

Interventions

  • BiologicalTTAX03

    Lyophilized and Micronized Particulate Human Amniotic and Umbilical Cord

  • BiologicalSaline

    2 mL Sterile, preservative free 0.9% NaCl

06

What researchers measure

Primary outcomes

  1. Pain Relief and/or Functional Improvement

    Proportion of subjects who, at the end of 12 weeks, report improvement from baseline in pain or in function \> or = 50% and absolute change \> or = 20; \- or - Improvement in at least 2 of the 3 following: * pain \> or = 20% and absolute change \> or = 10 * function \> or = 20% and absolute change \> or = 10 * global assessment \> or = 20% and absolute change \> or = 10

    Time frame: 12-weeks post Intra-articular Injection

Secondary outcomes

  1. KOOS Knee Symptoms Subscale

    Change from Baseline as a result of the intervention on joint symptoms

    Time frame: 6,12, 26, 39 & 52 weeks from Baseline versus Saline

  2. KOOS Knee Pain Subscale

    Change from Baseline as a result of the intervention on Knee Pain

    Time frame: 6,12, 26, 39 & 52 weeks from Baseline versus Saline

  3. KOOS Physical Function Subscale

    Change from Baseline as a result of the intervention on Physical Function

    Time frame: 6,12, 26, 39 & 52 weeks from Baseline versus Saline

  4. KOOS Sports and Recreation Subscale

    Change from Baseline as a result of the intervention on Sports and Recreation activities

    Time frame: 6,12, 26, 39 & 52 weeks from Baseline versus Saline

  5. KOOS Quality of Life Subscale

    Change from Baseline as a result of the intervention on joint-specific Quality of Life

    Time frame: 6,12, 26, 39 & 52 weeks from Baseline versus Saline

  6. Patient Global Impression of Change Questionnaire

    Change from Baseline as a result of the intervention on patient reported Global Impression of Change

    Time frame: 12, 26, 39 & 52 weeks from Baseline versus Saline

  7. Overall Change in Pain Relief Medication Use from Baseline

    Change in time to and frequency of use of pain relief medications and intra-articular injection of steroids and/or HA

    Time frame: Over the 52 weeks from Baseline versus Saline

07

Study locations

10 sites
  • UAB Orthopaedic Surgery
    Birmingham, Alabama 35205, United States
  • Alabama Orthopaedic Center
    Birmingham, Alabama 35243, United States
  • Tuscon Orthopedic Institute
    Tucson, Arizona 85712, United States
  • Horizon Clinical Research
    La Mesa, California 91942, United States
  • Gulfcoast Research Institute
    Sarasota, Florida 34232, United States
  • Precision Clinical Research
    Sunrise, Florida 33351, United States
  • Paragon Sports Medicine
    Atlanta, Georgia 30327, United States
  • Ochsner Health Center
    Jefferson, Louisiana 70121, United States
  • Manage Sites/The Ohio State University Wexner Medical Center, Sports Medicine The Ohio State University Wexner Medical Center, Sports Medicine
    Columbus, Ohio 43201, United States
  • Rothman Orthopaedic Institute
    Media, Pennsylvania 19063, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Mar 2025, 39 months.

Of 58 industry-sponsored phase 2 interventional studies under Osteoarthritis, Knee, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 25. This study's 39 months is above that.

Counting every sponsor, half of 101 studies reached it within 20 months; a quarter within 12 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2021
First posted
Oct 15, 2021
StartActual
Dec 6, 2021
Primary completionActual
Mar 7, 2025
CompletionActual
Mar 7, 2025
Last update
Sep 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05079035
Lead sponsor
BioTissue Holdings, Inc
Responsible party
Sponsor
First posted
Oct 15, 2021
Start date
Dec 6, 2021
Primary completion
Mar 7, 2025
Completion
Mar 7, 2025
Last update
Sep 19, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TTAX-03

Start the discussion